Pfizer Return on Tangible Equity 2012-2026 | PFE
Current and historical return on tangible equity values for Pfizer (PFE) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Unlock Macrotrends Premium
Start 7-Day Free Trial
Pfizer Return On Tangible Equity Historical Data
Date
TTM Net Income
Tangible Equity
Return on Tangible Equity
2025-09-30
$9.83B
$-31.81B
-30.90%
2025-06-30
$10.75B
$-33.98B
-31.64%
2025-03-31
$7.88B
$-36.23B
-21.76%
2024-12-31
$8.03B
$-38.18B
-21.03%
2024-09-30
$4.25B
$-40.17B
-10.59%
2024-06-30
$-2.60B
$-29.81B
8.71%
2024-03-31
$-0.31B
$-17.80B
1.74%
2023-12-31
$2.12B
$-5.97B
-35.51%
2023-09-30
$10.48B
$5.18B
202.57%
2023-06-30
$21.47B
$7.64B
281.19%
2023-03-31
$29.05B
$8.19B
354.91%
2022-12-31
$31.37B
$6.91B
453.96%
2022-09-30
$29.77B
$7.40B
402.58%
2022-06-30
$29.31B
$3.61B
811.15%
2022-03-31
$24.97B
$-0.23B
-10680.64%
2021-12-31
$21.98B
$-3.12B
-703.67%
2021-09-30
$19.43B
$-7.51B
-258.89%
2021-06-30
$12.76B
$-13.88B
-91.88%
2021-03-31
$10.68B
$-19.02B
-56.16%
2020-12-31
$9.16B
$-23.70B
-38.64%
2020-09-30
$7.73B
$-24.77B
-31.20%
2020-06-30
$13.94B
$-26.50B
-52.60%
2020-03-31
$15.50B
$-26.26B
-59.02%
2019-12-31
$16.03B
$-26.44B
-60.60%
2019-09-30
$16.22B
$-27.99B
-57.94%
2019-06-30
$12.65B
$-27.24B
-46.45%
2019-03-31
$11.48B
$-28.70B
-39.99%
2018-12-31
$11.15B
$-29.99B
-37.19%
2018-09-30
$23.82B
$-32.03B
-74.36%
2018-06-30
$22.55B
$-35.89B
-62.82%
2018-03-31
$21.75B
$-39.73B
-54.73%
2017-12-31
$21.31B
$-43.43B
-49.06%
2017-09-30
$9.81B
$-46.99B
-20.88%
2017-06-30
$8.32B
$-47.55B
-17.51%
2017-03-31
$7.30B
$-43.28B
-16.86%
2016-12-31
$7.22B
$-37.40B
-19.29%
2016-09-30
$6.27B
$-31.48B
-19.91%
2016-06-30
$7.04B
$-25.60B
-27.51%
2016-03-31
$7.62B
$-19.91B
-38.29%
2015-12-31
$6.96B
$-15.85B
-43.91%
2015-09-30
$8.36B
$-11.36B
-73.63%
2015-06-30
$8.90B
$-5.71B
-155.92%
2015-03-31
$9.18B
$-4.52B
-203.23%
2014-12-31
$9.14B
$-3.00B
-304.70%
2014-09-30
$10.48B
$-2.92B
-359.26%
2014-06-30
$10.40B
$-3.87B
-268.97%
2014-03-31
$21.58B
$-4.41B
-489.67%
2013-12-31
$22.00B
$-5.04B
-436.94%
2013-09-30
$25.75B
$-5.50B
-468.44%
2013-06-30
$26.37B
$-6.71B
-392.72%
2013-03-31
$15.53B
$-8.66B
-179.32%
2012-12-31
$14.57B
$-10.99B
-132.53%
2012-09-30
$9.69B
$-12.50B
-77.59%
2012-06-30
$10.22B
$-12.75B
-80.20%
2012-03-31
$9.58B
$-12.80B
-74.87%
2011-12-31
$10.01B
$-12.41B
-80.67%
2011-09-30
$11.46B
$-12.43B
-92.21%
2011-06-30
$8.59B
$-13.40B
-64.11%
2011-03-31
$8.45B
$-14.72B
-57.43%
2010-12-31
$8.26B
$-15.78B
-52.34%
2010-09-30
$6.13B
$-17.46B
-35.14%
2010-06-30
$8.15B
$-6.79B
-119.98%
2010-03-31
$7.93B
$4.04B
196.24%
2009-12-31
$8.64B
$13.81B
62.52%
2009-09-30
$8.13B
$23.44B
34.71%
2009-06-30
$7.53B
$23.11B
32.61%
2009-03-31
$8.05B
$23.15B
34.77%
2008-12-31
$8.10B
$24.13B
33.59%
2008-09-30
$10.56B
$25.27B
41.79%
2008-06-30
$9.05B
$24.62B
36.74%
2008-03-31
$7.54B
$24.43B
30.85%
2007-12-31
$8.14B
$24.95B
32.64%
2007-09-30
$14.87B
$25.70B
57.85%
2007-06-30
$17.47B
$25.44B
68.68%
2007-03-31
$18.62B
$24.71B
75.34%
2006-12-31
$19.34B
$22.14B
87.34%
2006-09-30
$12.62B
$20.24B
62.35%
2006-06-30
$10.85B
$17.91B
60.55%
2006-03-31
$11.90B
$15.57B
76.40%
2005-12-31
$8.09B
$14.34B
56.40%
2005-09-30
$8.18B
$12.52B
65.33%
2005-06-30
$9.93B
$11.94B
83.18%
2005-03-31
$9.33B
$11.31B
82.48%
2004-12-31
$11.36B
$10.50B
108.23%
2004-09-30
$9.14B
$9.56B
95.57%
2004-06-30
$8.03B
$9.48B
84.72%
2004-03-31
$1.58B
$9.81B
16.07%
2003-12-31
$3.91B
$13.32B
29.37%
2003-09-30
$6.17B
$15.89B
38.79%
2003-06-30
$6.28B
$17.46B
35.97%
2003-03-31
$11.83B
$19.16B
61.74%
2002-12-31
$9.13B
$17.72B
51.51%
2002-09-30
$8.23B
$17.41B
47.25%
2002-06-30
$7.95B
$17.28B
46.00%
2002-03-31
$7.82B
$16.91B
46.26%
2001-12-31
$7.79B
$16.43B
47.40%
2001-09-30
$7.25B
$15.85B
45.74%
2001-06-30
$6.54B
$15.17B
43.11%
2001-03-31
$5.86B
$14.45B
40.55%
2000-12-31
$3.73B
$12.83B
29.06%
2000-09-30
$3.26B
$11.28B
28.90%
2000-06-30
$3.30B
$9.68B
34.05%
2000-03-31
$2.86B
$8.36B
34.16%
1999-12-31
$3.88B
$8.07B
48.04%
1999-09-30
$3.63B
$8.03B
45.21%
1999-06-30
$3.63B
$7.97B
45.56%
1999-03-31
$3.55B
$7.83B
45.38%
1998-12-31
$3.43B
$7.49B
45.77%
1998-09-30
$3.28B
$7.15B
45.80%
1998-06-30
$2.47B
$6.73B
36.75%
1998-03-31
$2.30B
$6.37B
36.16%
1997-12-31
$2.21B
$6.08B
36.38%
1997-09-30
$2.16B
$5.81B
37.18%
1997-06-30
$2.08B
$5.56B
37.38%
1997-03-31
$2.01B
$5.23B
38.54%
1996-12-31
$1.93B
$4.92B
39.19%
1996-09-30
$1.84B
$4.61B
39.87%
1996-06-30
$1.75B
$4.36B
40.07%
1996-03-31
$1.67B
$4.14B
40.36%
1995-12-31
$1.57B
$3.87B
40.65%
1995-09-30
$1.50B
$3.80B
39.34%
1995-06-30
$1.41B
$3.74B
37.63%
1995-03-31
$1.35B
$3.71B
36.33%
1994-12-31
$1.30B
$3.74B
34.71%
1994-09-30
$1.25B
$3.65B
34.34%
1994-06-30
$0.70B
$3.59B
19.56%
1994-03-31
$0.70B
$3.69B
18.97%
1993-12-31
$0.66B
$3.82B
17.23%
1993-09-30
$0.65B
$4.00B
16.21%
1993-06-30
$1.16B
$4.38B
26.51%
1993-03-31
$1.13B
$4.59B
24.55%
1992-12-31
$1.08B
$4.74B
22.71%
1992-09-30
$0.80B
$4.82B
16.56%
1992-06-30
$0.78B
$4.69B
16.53%
1992-03-31
$0.73B
$4.60B
15.95%
1991-12-31
$0.72B
$4.60B
15.71%
1991-09-30
$0.88B
$4.58B
19.14%
1991-06-30
$0.84B
$4.56B
18.50%
1991-03-31
$0.82B
$4.53B
18.03%
1990-12-31
$0.80B
$4.42B
18.11%
1990-09-30
$0.73B
$4.30B
17.04%
1990-06-30
$0.71B
$4.19B
16.90%
1990-03-31
$0.69B
$4.11B
16.88%
1989-12-31
$0.68B
$4.06B
16.82%
1989-09-30
$0.74B
$4.74B
15.54%
1989-06-30
$0.74B
$4.68B
15.74%
1989-03-31
$0.81B
$4.67B
17.41%
1988-12-31
$0.79B
$4.60B
17.21%
1988-09-30
$0.79B
$3.80B
20.70%
1988-06-30
$0.76B
$3.73B
20.28%
1988-03-31
$0.72B
$3.61B
19.92%
1987-12-31
$0.69B
$3.50B
19.75%
Sector
Industry
Market Cap
Revenue
Medical Large Cap Pharmaceutical $153.074B
$62.579B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
